Study of Cognitive Dysfunction and Diabetes
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Enrollment
- 400
- Locations
- 3
- Primary Endpoint
- MMSE Olfactory function dementia
Study Overview
Brief Summary
The rate of cognitive decline due to ageing is increased 1.5-fold to 2.0-fold in individuals with type 2 diabetes.There are no established specific treatment measures to prevent or ameliorate cognitive impairments in patients with diabetes. we want to detecte early clinical dementia in diabete.
Detailed Description
Clinically relevant cognitive decrements in relation to diabetes mainly occur during two crucial periods in life: the period of brain development in childhood, and the period when the brain undergoes neurodegenerative changes associated with ageing.Potential leads for treatment are to optimise glycaemic control and avoid and treat vascular risk factors.we want to detecte early clinical dementia in diabete by MMSE and Olfactory function.
Study Design
- Study Type
- Observational
- Observational Model
- Case Control
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 50 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Patients with type 2 diabetes(Age>50 years)
Exclusion Criteria
- •with stroke or other complications.
Outcomes
Primary Outcomes
MMSE Olfactory function dementia
Time Frame: 2 years
MMSE,Olfactory function and PET(fMRI) were observed.
Secondary Outcomes
No secondary outcomes reported
Investigators
zhipeng xu
doctor
Wuhan General Hospital of Guangzhou Military Command